Evidence map›Paper›PMID 35293952›Full record

ArticleInvestigative ophthalmology & visual science2022

The RUSH2A Study: Dark-Adapted Visual Fields in Patients With Retinal Degeneration Associated With Biallelic Variants in the USH2A Gene.

David G Birch, Lassana Samarakoon, Michele Melia, Jacque L Duncan, Allison R Ayala, Isabelle Audo, Janet K Cheetham, Todd A Durham, Alessandro Iannaccone, Mark E Pennesi and 2 more

Open access · goldAbstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. ISCEV and IPS guideline for the full-field stimulus test (FST).Documenta ophthalmologica. Advances in ophthalmology · 2024
    Guideline
  2. Review
  3. Development of a conceptual, HOV-inspired spatial weighting model for quantifying geographic atrophy severity.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. [Gene therapy in ophthalmology].Die Ophthalmologie · 2023
    Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 3 countries.

David G BirchRetina Foundation of the Southwest, Dallas, Texas, United States.
Lassana SamarakoonJaeb Center for Health Research, Tampa, Florida, United States.
Michele MeliaJaeb Center for Health Research, Tampa, Florida, United States.
Jacque L DuncanUniversity of California, San Francisco, San Francisco, California, United States.
Allison R AyalaJaeb Center for Health Research, Tampa, Florida, United States.
Isabelle AudoInstitut de la Vision, Sorbonne Université, INSERM, CNRS, Paris, France.
Janet K CheethamFoundation Fighting Blindness, Columbia, Maryland, United States.
Todd A DurhamFoundation Fighting Blindness, Columbia, Maryland, United States.
Alessandro IannacconeDuke University Medical School, Duke Eye Center, Department of Ophthalmology, Durham, North Carolina, United States.
Mark E PennesiCasey Eye Institute - Oregon Health & Science University, Portland, Oregon, United States.
Katarina StinglUniversity Eye Hospital, Center for Ophthalmology, University of Tübingen, Tübingen, Germany.
Foundation Fighting Blindness Consortium Investigator Group
Jaeb Center for Health Research · USFoundation Fighting Blindness · USDuke University · USInserm · FROregon Health & Science University · USRetina Foundation of the Southwest · USSTZ eyetrial · DEUniversity of California, San Francisco · US

Funding

MEASURES OF HUMAN RECEPTOR AND POST RECEPTOR ACTIVITYR01EY009076 · NEI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI BIRCH, DAVID G, HOOD, DONALD C. · 1991 to 2021
$8.3M
Foundation Fighting Blindness RUSH2A - CONSORTIUM - 2016NEI NIH HHS R01 EY009076
6 · The paper itself

Abstract

Purpose: To measure visual fields using two-color dark-adapted chromatic perimetry in a subset of participants in the Rate of Progression of USH2A-related Retinal Degeneration (RUSH2A), a study of USH2A-mediated syndromic (USH2) and autosomal recessive nonsyndromic retinitis pigmentosa, determine percentage retaining rod function, and explore relationships between dark-adapted visual fields (DAVF) and rod function from ERG and full-field stimulus thresholds (FST). Methods: Full-field rod mean sensitivity, number of rod loci, maximum sensitivity, DAVF full-field hill of vision (DAVF VTOT), and 30° hill of vision (DAVF V30) were measured in one eye for DAVF ancillary study participants (n = 49). Loci where cyan relative to red sensitivity was more than 5 dB on dark-adapted chromatic perimetry were considered rod mediated. Correlation coefficients between the DAVF measures and standard clinical measures were estimated, as were kappa statistics (κ) for agreement between DAVF and other measures of rod function. Results: Of 49 participants tested with DAVF, 38 (78%) had evidence of rod function, whereas 15 (31%) had measurable rod ERGs. DAVF maximum sensitivity was highly correlated with FST white thresholds (r = -0.80; P < .001). Although not statistically significant, the number of rod loci and DAVF VTOT were lower in eyes with longer disease duration by 0.82 (95% confidence interval, -1.76, 0.12) loci/year and 0.59 (95% confidence interval, -1.82, 0.64) dB-steradians/year, respectively. Conclusions: Rod-mediated function on FST and DAVF is present in many patients with symptomatic USH2A-related retinal degeneration, including some without measurable rod ERGs. RUSH2A longitudinal data will determine how these measures change with disease progression and whether they are useful for longitudinal studies in inherited retinal degenerations.

Indexed as

Retinal DegenerationRetinitis PigmentosaDark AdaptationExtracellular Matrix ProteinsHumansUsher SyndromesVisual FieldsVisual Field TestsExtracellular Matrix ProteinsUSH2A protein, human

Identifiers

PMID35293952
PMCPMC8944389
OpenAlexW4220717312

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.